Sector Expert: Grant Zeng

Zacks Investment Research , Zacks Small-Cap Research

Image: Grant Zeng

Grant Zeng has more than 10 years' professional experience in equity research and analysis. He is currently a senior biotech analyst with Zacks Investment Research Inc., and has been with Zacks since March 2006. Before joining Zacks, Zeng worked for TheStreet.com as a biotech analyst from 2005-2006. From September 2001 to December 2003, Zeng worked for China Pacific Insurance Co. as an equity/fund analyst. Zeng was a healthcare equity analyst with Young & Partners LLC from August 2000 to September 2001. Zeng also has teaching and research experience in pharmaceutical science. Zeng obtained his master's of business administration with a major in finance in 2000 from McMaster University, Canada. He also holds a master's degree in biochemistry from the University of Western Ontario, Canada, and earned a master's degree in pharmacology and bachelor's degree in medicine from Second Military Medical University in China. Zeng is a Chartered Financial Analyst (CFA).



Recent Interviews

Build Biotech Wealth on Solid Platforms: Grant Zeng (4/17/14)

Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.

6 Biotechs with Staggering Potential: Grant Zeng (4/4/13)

When it comes to picking biotech stocks, does a buyside perspective matter more than a sellside? Not according to Zacks Investment Research Analyst Grant Zeng, who has straddled the divide. What really matters is research of uncompromised quality. In this interview with The Life Sciences Report, Zeng offers a primer on what he looks for in a biotech investment, and names companies with the potential for big returns.

Recent Quotes

"DRRX's DUR-928 is the most important program for Durect and the key value driver for the company in the long run."

— Grant Zeng, Zacks Equity Research (11/1/16)
more >

"SNGX announced that the FDA has granted orphan drug designation to dusquetide for treatment of macrophage activation syndrome."

— Grant Zeng, Zacks Equity Research (8/18/16)
more >

"We are especially optimistic about DRRX's epigenomic regulator DUR-928, which holds great market potential for multiple indications, including NAFLD/NASH and acute kidney injury."

— Grant Zeng, Zacks Equity Research (8/2/16)
more >

"SNGX's technology has the potential to provide adjunctive or stand-alone therapies for the broader antimicrobial/antibiotic antiviral, anti-inflammatory and anti-cancer markets."

— Grant Zeng, Zacks Equity Research (8/1/16)
more >

"SNGX's Dr. Lehrer has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates."

— Grant Zeng, Zacks Equity Research (7/18/16)
more >

"SNGX is developing vaccines using its ThermoVax technology for biodefense."

— Grant Zeng, Zacks Small-Cap Research (5/16/16)
more >

"We think DRRX has made great progress during the first quarter of 2016."

— Grant Zeng, Zacks Equity Research (5/6/16)
more >

"NIAID's exercise of the RiVax option not only boosts SNGX's balance sheet, it validates the company's vaccine technology."

— Grant Zeng, Zacks Small-Cap Research (5/6/16)
more >

more comments

"SNGX will be pursuing opportunities for partnership on SGX942 trials."

— Grant Zeng, Zacks Small-Cap Research (4/20/16)
more >

"The contract with NIAID provides up to $24.7M to support the preclinical, manufacturing and clinical development activities to advance SNGX's RiVax with the FDA."

— Grant Zeng, Zacks Small-Cap Research (3/31/16)
more >

"SNGX's Phase 2 study of SGX942 for the treatment of oral mucositis achieved all objectives."

— Grant Zeng, Zacks Small-Cap Research (12/17/15)
more >

"CPHR reported another strong quarter of financial results for Q3/15."

— Grant Zeng, Zacks Small-Cap Research (11/5/15)
more >

"We continue to be positive about the DRRX story."

— Grant Zeng, Zacks Small-Cap Research (11/3/15)
more >

— Grant Zeng, Zacks Small-Cap Research (9/8/15)
more >

"CPXX's fundamentals remain strong and we are optimistic about its prospects."

— Grant Zeng, Zacks Small-Cap Research (8/24/15)
more >

"We are pleased with the positive data from CPXX's Phase 3 trial."

— Grant Zeng, Zacks Small-Cap Research (7/28/15)
more >

"We expect CPXX's CPX-351 to be approved by the FDA in late 2017."

— Grant Zeng, Zacks Equity Research (6/24/15)
more >

"SNGX is on track to advance multiple clinical programs."

— Grant Zeng, Zacks Small-Cap Research (5/14/15)
more >

"CPXX's fundamentals are strong and we are optimistic about its prospects."

— Grant Zeng, Zacks Equity Research (5/11/15)
more >

"We maintain an Outperform rating for SNGX."

— Grant Zeng, Zacks Equity Research (4/14/15)
more >

"We think SNGX shares are undervalued."

— Grant Zeng, Zacks Equity Research (3/25/15)
more >

"SNGX is attractively valued and we're rating it as an outperform."

— Grant Zeng, Zacks Equity Research (3/2/15)
more >

"SGNX's SGX943 targets BPS, which is considered a top-five priority in the most recent PHEMCE strategy document."

— Grant Zeng, Seeking Alpha (2/18/15)
more >

fewer comments


Due to permission requirements, not all quotes are shown.